Gefitinib in non small cell lung cancer.
Gefitinib in non small cell lung cancer.
复制标题
DOI：
10.1155/2011/815269
复制
发表时间：
2011
影响因子：
--
通讯作者：
Morabito A
中科院分区：
文献类型：
--
作者：
Costanzo R;Piccirillo MC;Sandomenico C;Carillio G;Montanino A;Daniele G;Giordano P;Bryce J;De Feo G;Di Maio M;Rocco G;Normanno N;Perrone F;Morabito A
吉非替尼是一种口服、可逆、表皮生长因子受体 (EGFR) 酪氨酸激酶抑制剂，在非小细胞肺癌 (NSCLC) 的生物学中发挥着关键作用。 I 期研究表明吉非替尼的推荐剂量为 250mg/天。皮疹、腹泻和恶心是最常见的不良事件。吉非替尼早期 2 期临床试验中获得的阳性结果并未在针对未经选择的晚期 NSCLC 患者的大型 3 期试验中得到证实。随后发现 EGFR 激酶结构域中体细胞突变的存在与 EGFR 酪氨酸激酶抑制剂的反应性增强密切相关，这促使吉非替尼在 EGFR 突变 NSCLC 一线治疗中进行了 2 期和 3 期试验。这些试验的结果证明了吉非替尼的疗效，现在可以将吉非替尼视为携带激活 EGFR 突变的晚期 NSCLC 患者的标准一线治疗方法。
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefitinib were not confirmed in large phase 3 trials in unselected patients with advanced NSCLC. The subsequent discovery that the presence of somatic mutations in the kinase domain of EGFR strongly correlates with increased responsiveness to EGFR tyrosine kinase inhibitors prompted phase 2 and 3 trials with gefitinib in the first line-treatment of EGFR-mutated NSCLC. The results of these trials have demonstrated the efficacy of gefitinib that can be now considered as the standard first-line treatment of patients with advanced NSCLC harbouring activating EGFR mutations.
登录
查看更多内容
影响因子：
45.3
作者：
Giaccone, G;Herbst, RS;Johnson, DH
通讯作者：
Johnson, DH
影响因子：
45.3
作者：
Cappuzzo, Federico;Ligorio, Claudia;Varella-Garcia, Marileila
通讯作者：
Varella-Garcia, Marileila
影响因子：
50.5
作者：
D'Addario, G.;Rauch, D.;Betticher, D. C.
通讯作者：
Betticher, D. C.
影响因子：
45.3
作者：
Baselga, J;Rischin, D;Albanell, J
通讯作者：
Albanell, J
影响因子：
45.3
作者：
Crino, Lucio;Cappuzzo, Federico;Cullen, Michael
通讯作者：
Cullen, Michael